A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

• ClinicalTrials.gov Identifier: NCT04649489
• Recruitment Status: Recruiting
• First Posted: December 2, 2020
• Last Update Posted: March 3, 2022
• Sponsor: Fudan University
• Information provided by (Responsible Party): Jia Fan, Fudan University

Study Description

Brief Summary:

The treatment strategies for HCC with PVTT is still controversial, and differ substantially between the west and the east. According to western guidelines, including those of the EASL, BCLC, and AASLD, PVTT is regarded as a contra-indication to initial surgery or transarterial chemoembolization.

At present, there is still no consensus on the diagnosis and treatment standards of HCC with HVTT/IVCTT. European and American guidelines for liver cancer use The Barcelona Clinic Liver Cancer (BCLC) staging as the standard and classify liver cancer with HVTT/IVCTT into the advanced stage. Molecular targeted drugs such as sorafenib and lenvatinib are recommended to the patients in this phase as first-line treatment drugs and methods. In this regard, experts in China and Southeast Asian countries still have different opinions. They believe that surgery, transarterial chemoembolization (TACE), radiotherapy, and combined treatment with multiple treatment methods can achieve more satisfactory results.

HCC with VTT consists of heterogeneous populations with different disease behaviors and prognoses. As a result of recent concept evolution and advances in surgical techniques and perioperative management, emerging evidence shows that selected patients with PVTT may benefit from more aggressive treatment modalities, which are recommended for by Chinese, Japanese, South Korean, and Asia Pacific clinical practice guidelines. A national survey from Japan showed median overall survival with liver resection treatment to be 1.77 years longer than with nonresection therapies, which included TACE, radiotherapy, sorafenib, or conservative treatment (2.87 years vs 1.10 years, respectively; p<0.001). After propensity-score matching of patient baseline characteristics, median overall survival since diagnosis in the liver resection group was 0.88 years longer than in the non-resection group. In a large-scale, multicentre, propensity-score matched analysis from China, surgery was the best treatment for patients with Cheng's type I and II PVTT with Child-Pugh A and selected B liver function. Median overall survival after liver resection (745 of 1580 patients) was 15.9 months (95% CI 13.3-18.5 months) for Cheng's type I PVTT and 12.5 months (10.7-14.3 months) for Cheng's type II PVTT. Thus, aggressive surgical resection in selected patients with HCC with vascular invasion, as proposed by several tertiary health-care centers in the east, seems to be reasonable.

Currently, there are no dedicated clinical trials to study the value of hepatic resection in this population. Furthermore, cumulative evidence indicates that long-term overall survival after hepatic resection alone remains unsatisfactory because of the high rate of tumor recurrence and correspondingly low rate of disease-free survival. The combination of perioperative therapies may be more efficacious to improve the prognosis in selected population. More high-level evidence of novel multimodality treatment should be generated.

This trial will enroll HCC patients with PVTT CNLC Stage IIIa, who have no prior anti-cancer treatment. Given the poor prognosis and limited treatment options for these patients, this population is considered appropriate for trials of more aggressive and novel therapeutic candidates in the initial treatment setting. The benefit risk profile for hepatic resection combined with perioperative atezo/bev in this patient population is expected to be favorable.

Condition or disease	Intervention/treatment
Hepatic Venous Thrombosis	Drug: Atezolizumab; Procedure: Surgery

Detailed Description:

This is a multicenter, open-label, two-arm, randomized study designed to evaluate the efficacy and safety of surgical resection plus peri-operative atezo/bev compared with continuous systemic atezo/bev in HCC patients with VTT and without EHS.

Initially eligible patients will be enrolled into induction phase, during which they will receive 3 cycles of atezo/bev and 1 cycle of atezo alone as primary systemic therapy. Tumor response assessment using computed tomography (CT) and/or magnetic resonance imaging (MRI) will be conducted by the Independent-Review Facility (IRF) according to RECIST v1.1 after cycle 2 and cycle 4.

Only those patients who are assessed as partial response (PR) or stable disease (SD) and considered suitable for curative hepatic resection will be randomized in a 1:1 ratio to one of the following two arms:

• Arm A (experimental arm): hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle
• Arm B (control arm): atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle

Randomization will be performed after the second tumor assessment and stratified according to the following stratification factors:

• Tumor response: target lesion reduction (maximum diameter reduction ≥10% compared with the entry baseline) vs non-reduction
• Eastern Cooperative Oncology Group (ECOG) performance status: 0 vs 1 Those patients who are assessed as disease progression (PD) or complete response (CR) and/or not suitable for curative hepatic resection will be excluded from randomization and treated according to local practice (Patients without PD may continue atezo/bev treatment at investigators' discretion).

In Arm A, hepatic resection surgery will be performed 0-2 weeks after the randomization. Surgical approaches will be tailored to the individual patient according to local standards with the goal of achieving R0 resection. The first administration of postoperative atezo/bev treatment is recommended to start within 4-6 weeks after surgery, requiring full recovery from the surgery prior to post-operative atezo/bev treatment, including:

• Adverse events emerged from prior treatment, if any, should have been recovered to meet the requirements of atezo/bev treatment according to investigator's judgement.
• No significant medical events (e.g., gastrointestinal [GI] bleeding, cardiac events, hepatorenal syndrome, biliary fistula, serious infection, etc.) during or after the surgery procedure Treatment with atezo/bev will continue until loss of clinical benefit (determined by the investigator), or unacceptable toxicity, withdrawal of ICF, death, or the study is terminated by the Sponsor, whichever occurs first. For Arm A, whether to continue atezo/bev treatment will be determined by the investigator at the end of the 12-month treatment period if none of the above occurs.

Tumor assessments will be performed in induction phase after cycle 2 and cycle 4 (randomization baseline), and in treatment period at regular intervals (Arm A will receive tumor assessment at the first dose of postoperative treatment (±3 days）and every 9 weeks (±7 days）thereafter. Arm B every 9 weeks (±7 days）thereafter ). Additional scans will be performed as clinically indicated. Following completion or discontinuation of the treatment, information on recurrence or disease progression, survival and subsequent anti-cancer therapies will be collected until death, loss to follow-up, withdrawal of ICF or study termination by Sponsor, whichever occurs first. In the absence of disease recurrence or progression, tumor assessments should continue regardless of whether patients start a new anti-cancer therapy, until documented treatment failure events, withdrawal of ICF or study termination. All patients will be followed for survival unless consent is withdrawn.

Patients who withdraw from the study will not be replaced. An IRF will be used to enable centralized, independent reviews of images and other clinical data (e.g., histopathology, tumor markers etc.) used for assessment of HCC response, recurrence and disease progression. IRF reviews will be performed prior to the pre-specified efficacy analyses. IRF membership and procedures will be detailed in an IRF Charter.

Study Design

• Study Type: Observational
• Estimated Enrollment: 198 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: A Multicenter, Randomized, Open-label Study Evaluating the Efficacy and Safety of Hepatic Resection for Hepatocellular Carcinoma With Venous Tumor Thrombosis After Initial Atezolizumab Plus Bevacizumab Treatment
• Actual Study Start Date: April 19, 2021
• Estimated Primary Completion Date: April 24, 2026
• Estimated Study Completion Date: October 23, 2026

Groups and Cohorts

Group/Cohort	Intervention/treatment
Arm A (experimental arm); hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle	Procedure: Surgery; hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg; Other Names: Atezolizumab; Bevacizumab
Arm B (control arm); atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle	Drug: Atezolizumab; atezolizumab 1200mg and bevacizumab 15mg/kg; Other Name: Bevacizumab

Outcome Measures

Primary Outcome Measures :

1. TTF [ Time Frame: 24 months ]
   Time-to-treatment failure (TTF) after randomization, defined as the time from randomization to the first documented treatment failure (i.e., local recurrence or progression, EHS, or death from any cause). Tumor response will be determined by the IRF according to RECIST v1.1

Secondary Outcome Measures :

1. OS [ Time Frame: 24 months ]
   Overall survival (OS) after randomization, defined as the time from randomization to death from any cause
2. OS rate [ Time Frame: 24 months ]
   OS rate at 12 months, 18 months and 24 months, defined as the proportion of patients who have not experienced death from any cause at 12, 18 and 24months after randomization, respectively
3. TTF [ Time Frame: 24 months ]
   TTF after randomization as determined by the investigator according to RECIST v1.1
4. TTF [ Time Frame: 24 months ]
   TTF after randomization as determined by the IRF and the investigator according to HCC mRECIST
5. Time to EHS [ Time Frame: 24 months ]
   Time to EHS after randomization, defined as the time from randomization to first appearance of EHS, as determined by the IRF and the investigator

Other Outcome Measures:

1. AE/ADR [ Time Frame: 24 months ]
   Nature, incidence, severity and seriousness of the adverse events/ADR. Adverse events are graded according to the NCI-CTCAE (Version 5.0)
2. Pulse rate [ Time Frame: 24 months ]
   Changes from randomization baseline in pulse rate
3. Respiratory rate [ Time Frame: 24 months ]
   Changes from randomization baseline in respiratory rate
4. blood pressure [ Time Frame: 24 months ]
   Changes from randomization baseline in blood pressure
5. Body temperature [ Time Frame: 24 months ]
   Changes from randomization baseline in body temperature
6. Physical findings [ Time Frame: 24 months ]
   Changes from randomization baseline in targeted physical findings
7. Hematology [ Time Frame: 24 months ]
   Changes from randomization baseline in hematology test result
8. Serum chemistry [ Time Frame: 24 months ]
   Changes from randomization baseline in serum chemistry test result
9. Serology [ Time Frame: 24 months ]
   Changes from randomization baseline in serology test result
10. Blood coagulation [ Time Frame: 24 months ]
    Changes from randomization baseline in blood coagulation test result
11. Pregnency [ Time Frame: 24 months ]
    Changes from randomization baseline in pregnency test result
12. Urinalysis [ Time Frame: 24 months ]
    Changes from randomization baseline in urinalysis test result
13. C-reactive protein [ Time Frame: 24 months ]
    Changes from randomization baseline in C-reactive protein test result
14. α-fetoprotein [ Time Frame: 24 months ]
    Changes from randomization baseline in α-fetoprotein test result
15. TSH [ Time Frame: 24 months ]
    Changes from randomization baseline in TSH(thyroid-stimulating hormone) test result
16. Free or total T3 [ Time Frame: 24 months ]
    Changes from randomization baseline in free or total T3(Triiodothyronine) test result
17. Free T4 [ Time Frame: 24 months ]
    Changes from randomization baseline in free T4(Thyroxine) test result
18. RFS [ Time Frame: 24 months ]
    Recurrence-free survival (RFS) after randomization (Arm A), defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC as determined by the IRF and the investigator, or death from any cause (whichever occurs first)
19. TTR [ Time Frame: 24 months ]
    Time-to-Recurrence (TTR) after randomization (Arm A), defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC, as determined by the IRF and the investigator
20. R0 rate [ Time Frame: 24 months ]
    R0 rate (Arm A), defined as the proportion of patients who accomplish the complete resection of tumor with pathologically confirmed negative margin
21. pCR rate [ Time Frame: 24 months ]
    Pathological complete regression (pCR) rate (Arm A), defined as the proportion of patients with no evidence of vital residual tumor cells on the complete resected specimen. pCR status will be analyzed by local pathologists at each site
22. ORR [ Time Frame: 24 months ]
    Objective response rate (ORR) during atezo/bev treatment in induction phase before randomization and in Arm B after randomization, defined as the proportion of patients with a complete response (CR) or partial response (PR), as determined by the IRF and the investigator according to RECIST v1.1 and HCC mRECIST

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT), hepatic vein tumor thrombosis (HVTT) or inferior vena cava tumor thrombosis(IVCTT) and without extrahepatic spread (EHS), who are amenable for surgical resection after initial atezolizumab plus bevacizumab (atezo/bev) induction treatment.

Criteria

Inclusion Criteria:

• Signed Informed Consent Form (ICF)
• Aged ≥18 years at time of signing ICF
• Ability to comply with the study protocol, in the investigator's judgment
• Documented diagnosis of HCC confirmed by histology/cytology or clinically by AASLD criteria in cirrhotic patients Patients without cirrhosis require histological confirmation of diagnosis.
• No prior anti-tumor treatment (including both local-regional and systemic therapies) for HCC Previous use of herbal therapies/traditional Chinese medicines (TCM) with anti-cancer activity included in the label is allowed, provided that these medications are discontinued prior to randomization.
• Presence of PVTT, determined based on the radiological findings, including Vp1 (third-order branch of portal vein) to Vp4 (main trunk/collateral branch of portal vein) according to the Japanese staging system or
• Presence of HVTT or IVCTT, without atrium tumor thrombosis, determined based on the radiological findings
• Remnant liver volume-to-total liver volume (RLV%) ≥ 25%
• At least one measurable lesion (per RECIST v1.1) untreated lesion
• ECOG performance status of 0 or 1 within 7 days prior to study entry
• Child-Pugh class A within 7 days prior to study entry
• Life expectancy ≥12 weeks
• Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of induction treatment unless otherwise specified:
• Absolute neutrophil count (ANC)≥1.5x109/L (1500/uL) without granulocyte colony stimulating factor support
• Lymphocyte count ≥0.5x109/L (500/uL)
• Platelet count ≥75x109/L (75,000/uL) without transfusion
• Hemoglobin ≥90 g/L (9 g/dL). Patients may be transfused to meet this criterion.
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤5x upper limit of normal (ULN)
• Serum total bilirubin ≤3x ULN
• Serum albumin ≥28 g/L (2.8 g/dL)

• Serum creatinine (SCr) ≤1.5 x ULN or Creatinine clearance (CCr) ≥ 50mL/min (calculated using the Cockcroft-Gault formula):

  (140-age) x Weight (kg) CCr (ml/min) = --------------------------------- (Female x 0.85) 72 x SCr (mg/dL) (140-age) x Weight (kg) OR CCr (ml/min) = ----------------------------------- (Female x 0.85) 0.818 x SCr (umol/L)

• For patients not receiving therapeutic anticoagulation: international normalized ratio (INR) or activated partial prothrombin time (aPTT) ≤ 1.2 x ULN
• Urine dipstick for proteinuria < 2+ (within 7 days prior to Day 1 of Cycle 1) Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.
• Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade ≤ 1 prior to study entry, with the exception of alopecia
• Negative human immunodeficiency virus (HIV) test at screening
• Documented virology status of hepatitis, as confirmed by screening hepatitis B virus (HBV) and hepatitis C virus (HCV) serology tests
• For patients with positive HBsAg :
• HBV DNA < 500 IU/mL obtained within 28 days prior initiation of atezo/bev treatment. If the patients have received anti-HBV treatment, they should continue the same treatment for the length of the study; if not, the patients should receive anti-HBV treatment for the length of the study (according to local standard of care, eg. entecavir).
• If HBV DNA > 500 IU/mL and having not received anti-HBV treatment, the treatment (per local standard of care; e.g., entecavir) for a minimum of 7 days prior to study entry and willingness to continue anti-HBV treatment for the length of the study. Retest of HBV-DNA prior to study entry should be more than 1-log decrease.
• If HBV DNA > 500 IU/mL and having received anti-HBV treatment, the treatment (per local standard of care; e.g., entecavir) for a minimum of 7 days prior to study entry and willingness to continue anti-HBV treatment for the length of the study. Retest of HBV-DNA prior to study entry should decrease.
• For women of childbearing potential, agreement (by patient) to remain abstinent (refrain from heterosexual intercourse) or to use contraceptive methods as defined below:
• Women must remain abstinent or use highly effective form(s) of contraception (i.e., one that results in a low failure rate [<1% per year] when used consistently and correctly) while they are receiving atezolizumab and bevacizumab and for at least 5 months after the final dose of atezolizumab and 6 months after the final dose of bevacizumab. Women must refrain donating eggs during this same period.
• A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgical sterilization (i.e., removal of ovaries, fallopian tubes and/or uterus), or other causes as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.
• Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices
• The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized acceptable methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.
• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:
• With female partners of childbearing potential or pregnant female partners, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 6 months after the final dose of bevacizumab to avoid exposing the embryo. Men must refrain from donating sperm during this same period
• The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of preventing drug exposure. If required per local guidelines or regulations, locally recognized acceptable methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.

Patients must meet the following additional criteria for study randomization:

• Tumor assessed as PR or SD after 4 cycles of atezo/bev treatment as determined by the IRF according to RECIST v1.1
• Feasibility for curative hepatic resection as assessed by the investigator
• Physical condition and organ function allowing to undergo appropriate surgical management or atezo/bev treatment according to investigator's judgement.
• Treatment emerged adverse events during induction phase, if any, should have been recovered to meet the requirements of surgical or atezo/bev treatment according to investigator's judgement.
• Agreement and ability to comply with the treatment of Arm A or Arm B in the investigator's judgment

Exclusion Criteria:

• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
• Evidence of EHS, as confirmed by CT and/or MRI scans of the chest, abdomen, and pelvis
• Evidence of HCC disease progression or complete remission prior to randomization
• Clinically significant ascites
• History of hepatic encephalopathy
• Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding
• Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Patients who have undergone an EGD within 6 months of prior to initiation of atezo/bev treatment do not need to repeat the procedure.
• Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:
• Patients with a history of autoimmune-related hypothyroidism who are on thyroidreplacement hormone are eligible for the study.
• Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
• Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
• Rash must cover < 10% of body surface area.
• Disease is well controlled at baseline and requires only low-potency topical corticosteroids.
• There is no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the 12 months prior to Day 1 of Cycle 1.
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
• Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to Day 1 of Cycle 1, unstable arrhythmia, or unstable angina
• History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
• Active tuberculosis
• Severe infection within 4 weeks prior to Day 1 of Cycle 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
• Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1
• Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
• Prior allogeneic stem cell or solid organ transplantation
• On the waiting list for liver transplantation
• Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
• Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of atezolizumab or within 6 months after the final dose of bevacizumab
• Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to Day 1 of Cycle 1.
• Co-infection with HBV and HCV
• Patients with a history of HCV infection but who are negative for HCV RNA by polymerase chain reaction will be considered to be negative for HCV infection.
• Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium, > 12mg/dL, or corrected serum calcium > ULN)
• History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
• Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulations
• Any prior treatment for HCC, including systemic therapy (including investigational agents) and locoregional therapy such as TACE
• Prior use of herbal therapies or traditional Chinese medicines with anti-cancer activity included in the label is allowed, but such therapies must be discontinued at least 7 days prior to study entry and are prohibited during the study.
• Treatment with a live, attenuated vaccine within 4 weeks prior to Day 1 of Cycle 1, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
• Treatment with investigational therapy within 4 weeks prior to Day 1 of Cycle 1
• Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
• Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 drug elimination half-lives (whichever is longer) prior to Day 1 of Cycle 1
• Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-α [TNF-α agents) within 2 weeks prior to Day 1 of Cycle 1, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:
• Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Medical Monitor approval has been obtained.
• Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
• Inadequately controlled arterial hypertension (defined as systolic blood pressure [BP] > 150 mmHg and/or diastolic BP > 100 mmHg), based on an average of at least three BP readings at two or more sessions
• Anti-hypertensive therapy to achieve these parameters is allowed.
• History of hypertensive crisis or hypertensive encephalopathy
• Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of Cycle 1 Clinical Study
• History of hemoptysis (> 2.5 mL of bright red blood per episode) within 1 month prior to Day 1 of Cycle 1
• Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
• Current or recent (within 10 days of Day 1 of Cycle 1) use of aspirin (> 325 mg/day) or current or recent treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol • Current or recent (within 10 days prior to Day 1 of Cycle 1) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose
• Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR and aPTT is within normal limits (according to institutional standards) within 14 days prior to Day 1 of Cycle 1.
• Prophylactic use of low-molecular-weight heparin (LMWH) (i.e., enoxaparin 40 mg/day) is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) is not recommended due to bleeding risk.
• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 3 days prior to Day 1 of Cycle 1
• History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation, or intraabdominal abscess within 6 months prior to Day 1 of Cycle 1
• Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure
• Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
• Major surgical procedure within 4 weeks prior to Day 1 of Cycle 1 or anticipation of need for a major surgical procedure during the study
• History of intra-abdominal inflammatory process within 6 months prior to Day 1 of Cycle 1, including, but not limited to, peptic ulcer disease, diverticulitis, or colitis
• History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding prior to initiation of study treatment Patients with signs/symptoms of sub-/occlusive syndrome/intestinal obstruction at time of initial diagnosis may be enrolled if they had received definitive (surgical) treatment for symptom resolution.
• Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment.
• Chronic daily treatment with a non-steroidal anti-inflammatory drugs (NSAIDs)
• Occasional use of NSAIDs for the symptomatic relief of medical conditions such asheadache or fever is allowed.

Contacts and Locations

Contacts

Contact: Jia Fan; +86-21-64041990; fan.jia@zs-hospital.sh.cn

Contact: Huichuan Sun; +86-13701922065; Sun.huichuan@zs-hospital.sh.cn

Locations

China, Shanghai

Zhongshan hospital, Fudan University; Recruiting

Shanghai, Shanghai, China, 200000

Sponsors and Collaborators

Fudan University

Investigators

• Principal Investigator: Jia Fan; Fudan University

More Information

• Responsible Party: Jia Fan, Director of hospital, Fudan University
• ClinicalTrials.gov Identifier: NCT04649489
• Other Study ID Numbers: ML42435
• First Posted: December 2, 2020
• Last Update Posted: March 3, 2022
• Last Verified: February 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Budd-Chiari Syndrome; Thrombosis; Venous Thrombosis; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Liver Diseases; Digestive System Diseases; Bevacizumab; Atezolizumab; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Physiological Effects of Drugs; Growth Inhibitors; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action; Immunologic Factors